Natural History of Amyloid Deposition in Adults With Down Syndrome (NCT01303133) | Clinical Trial Compass
CompletedNot Applicable
Natural History of Amyloid Deposition in Adults With Down Syndrome
United States81 participantsStarted 2009-08
Plain-language summary
The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive measures across a range of areas that are often affected by AD.
Who can participate
Age range30 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant IQ at least 47 (based upon Stanford-Binet V Abbrev. Test Battery)
✓. Participant at least 30 years of age
✓. DSDS score indicating participant is asymptomatic for AD
✓. Reliable caregiver who is capable of providing correct information about the participant's clinical symptoms and history
✓. Agreement of caregiver and clinician that participant is able to cooperate with the protocol tasks
✓. Participant has provided assent (or consent) and/or parent/caregiver has provided informed consent
Exclusion criteria
✕. Participant is non-verbal or has extremely limited language skills
✕. Score within the "symptomatic" range on the DSDS
✕. Any significant disease or unstable medical condition that could affect neuropsychological testing
✕. Any problems with vision or hearing that could affect neuropsychological testing
✕. Participants in whom MRI is contraindicated
✕. Claustrophobia or prior failed experiences of completing MRI scans or blood draws
✕. History or other evidence of severe illness or other condition that would make the participant, in the opinion of the investigator, unsuitable for the study?